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ABSTRACT
Objectives: Studies report that the risks of significant neurologic complications (including stroke,
cerebral abscess, and migraine) and hemorrhagic sequelae are high in patients with hereditary
hemorrhagic telangiectasia (HHT), and that life expectancy in this cohort is reduced. However,
most published cohorts derive from specialist centers, which may be susceptible to bias.
Methods: We used a population-based approach to estimate the risks of developing neurologic
and hemorrhagic complications of HHT, the association of a diagnosis of HHT with common car-
diovascular and malignant comorbidities, and also long-term survival of those with the disease.
Results: From a UK primary care database of 3.5 million patients (The Health Improvement Net-
work), we identified 675 cases with a diagnosis of HHT and compared them with 6,696 controls
matched by age, sex, and primary care practice. Risks of stroke (odds ratio [OR] 1.8, 95% confi-
dence interval [CI] 1.2–2.6), cerebral abscess (OR 30.0, CI 3.1–288), and migraine (OR 1.7, CI
1.3–2.2) were elevated over controls. Bleeding complications including epistaxis (OR 11.6, CI
9.1–14.7) and gastrointestinal hemorrhage (OR 6.1, CI 2.8–13.4) were more common in cases
with HHT. Survival of cases with HHT was poorer than controls with a hazard ratio for death of
2.0 (CI 1.6–2.6) and a median age at death 3 years younger.
Conclusions: Patients with HHT are at substantially increased risk of serious neurologic and hem-
orrhagic complications of the disease. Because a diagnosis of HHT is associated with a signifi-
cantly poorer survival compared with those who have no disease, evaluation of new strategies
to improve clinical management is required. Neurology® 2015;84:1886–1893
GLOSSARY
AVM 5 arteriovenous malformation; CI 5 confidence interval; HHT 5 hereditary hemorrhagic telangiectasia; HR 5 hazard
ratio; OR 5 odds ratio; THIN 5 The Heath Improvement Network.
Hereditary hemorrhagic telangiectasia (HHT) is a dominantly inherited genetic disorder of
blood vessel development characterized by epistaxis, mucocutaneous telangiectasia, and visceral
arteriovenous malformations (AVMs). It is estimated that between 1% and 10% of patients with
HHT have cerebral AVMs,1–3 and between 15% and 45% develop pulmonary AVMs.4,5 Neu-
rologic complications of HHT attributed to these AVMs include embolic stroke,6 cerebral
abscess,7,8 migraine,9,10 hemorrhagic stroke,2 and seizures.3 Although relatively rare compared
with other causes of stroke, AVMs are causally important because they have the potential to be
identified and treated in high-risk patients before complications develop. While embolization of
pulmonary AVMs may be associated with a reduced risk of neurologic sequelae,6 no consensus
exists as to the optimal management of cerebral AVMs.11,12
Many of the observational studies of the natural history of HHT are published from specialist
centers and are potentially susceptible to selection bias if the more severe cases are referred for
specialist care, possibly leading to an overestimate of the frequency and severity of complications
identified. While HHT undoubtedly causes significant morbidity in some, there are relatively
few published studies that have looked at survival in patients with the disease,13–16 the largest
of which included 113 individuals, limiting the provision of reliable estimates.16 Using a
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population-based UK primary care database
(The Heath Improvement Network [THIN]),
we undertook a matched case-control analysis
to investigate the association of various com-
plications and comorbidities with a diagnosis
of HHT, and to provide a population-based
estimate of survival in 675 individuals with
HHT compared with age- and sex-matched
controls.
METHODS THIN is a computerized primary care database
collecting information on patient demographics, diagnoses, con-
sultations (both in primary and secondary care), and prescrip-
tions. Data are entered prospectively by family physicians at the
point of care or, if derived from secondary care correspondence,
are entered retrospectively by administrative staff. The THIN
database has been validated for use in epidemiologic research
using associations observed in external primary care datasets rep-
licated in THIN17 and by auditing patients’ medical records and
comparing them with THIN data.18 Although the THIN data-
base was officially launched in 2003, many practices in the
United Kingdom were already using computerized software to
collect clinical information with some providing data to THIN
dating back as far as 1985. At the time of data extraction
(September 2011), THIN covered 5% of the UK population
with 3.5 million people contributing data across 550 primary care
practices,19 and is representative of the UK population.20,21 We
have recently used THIN to estimate the prevalence of HHT in
the United Kingdom.22
Case-control set. Cases were defined as those with a diagnosis of
HHT or Rendu-Osler-Weber disease coded in their THIN
computerized records between January 1, 1985, and September 1,
2011. THIN collects most data contemporaneously, although in
some cases historical data (from consultations before the start of a
practice contributing to THIN) are available because they
have been retrospectively added to the database. For the
majority of patients, an index date was set as the first
recorded diagnosis of HHT appearing in their existing records
and they were categorized as “contemporaneous” cases. If a
diagnosis of HHT was made before a patient’s practice began
contributing to THIN, then the date the practice joined THIN
and started to provide longitudinal data was set as the index date
(these individuals were categorized as “historical” cases). Each
case had a stop date defined as either the last date of data
collection within THIN or the date of death. Up to 10
control subjects who did not have a coded diagnosis of either
HHT or pulmonary AVMs and who were alive and
contributing data on each case’s index date were matched to
cases by age, sex, and primary care practice.
Data extraction and processing. We extracted data on age
(grouped in 3 categories: younger than 15 years, 15–49 years,
and 50 years and older), sex, socioeconomic status (as defined by
Townsend score in quintiles,23 including a category for missing
data), geographical location (defined by UK Health Authority),
smoking status (never smoker, ex-smoker, current smoker, or
unknown status), any complications potentially related to
HHT (anemia, cerebral abscess, dyspnea, epistaxis,
gastrointestinal bleeding, hemoptysis, intracerebral hemorrhage,
migraine, seizure, stroke, and TIA), common cardiovascular
comorbidities (ischemic heart disease, myocardial infarction,
cardiac failure, and venous thromboembolism), and solid organ
cancers (breast, lung, prostate, and bowel). The occurrence of any
complication was counted only once for each HHT case or
control. Date of death was extracted for any case or control
that died while contributing data to THIN.
Data analysis. Conditional logistic regression was used to
quantify the association between a diagnosis of HHT and the
occurrence of the differing complications potentially associated
with the disease when compared with control subjects. THIN
provided information on smoking status, diabetes, and hyperten-
sion, which were considered as possible a priori confounding var-
iables for some complications. Only smoking status differed
significantly between the cases and control groups and as such
we adjusted all crude odds ratios (ORs) solely for smoking status.
Survival analysis was performed using Kaplan–Meier methods,
comparing individuals who had HHT with controls. Start date
was set as the index date (defined above) and end date was date of
death or loss to follow-up. Cox regression analysis was used to
compare mortality rates between the 2 groups adjusting for
smoking status. We looked at survival differences stratified by
sex and socioeconomic group among the cases with HHT and
also explored survival of cases younger than 60 years vs those 60
years and older at the time of inclusion to the database, as a
previous study had reported a survival paradox with a subset of
younger patients with HHT having a higher mortality.14 The
Cox proportional hazards assumption was tested using log-
minus-log plots of survival and Schoenfeld residuals. A
sensitivity analysis was undertaken to look at complication
rates and survival outcomes in the contemporaneous cases with
HHT and the historical cases with HHT. No interactions were
considered in the statistical analysis plan. Data analysis was
performed using Stata statistical software version 12.0
(StataCorp, College Station, TX). The study was covered by
appropriate ethical approval.
RESULTS Six hundred seventy-five individuals with a
diagnosis of HHT or Rendu-Osler-Weber disease were
identified, together with a total of 6,696 controls. The
mean age of individuals with HHT was 53.8 years (SD
23.0 years) and 63% were female. Cases had a similar
socioeconomic distribution and a lower proportion of
never smokers (38.5% vs 42.4%) compared with
controls (table 1).
Complications. Univariate analysis determined that
ORs for several complications were significantly high-
er in cases with HHT than in matched controls,
including neurologic sequelae (cerebral abscess,
migraine, and ischemic/embolic stroke) and bleeding
complications (anemia, epistaxis, hemoptysis, and
gastrointestinal hemorrhage) (table 2). We did not
detect significantly increased odds of seizures, intra-
cerebral hemorrhage, TIA, or venous thromboembo-
lism in individuals with HHT. After adjustment for
smoking as a confounder, most ORs did not change
appreciably. The adjusted OR for cardiac failure was
higher in those with HHT, although not that of
ischemic heart disease or myocardial infarction. The
odds of colon cancer in individuals with HHT were
higher than those in controls, but there was no detect-
able difference in rates of other solid organ tumors.
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Survival analysis. The median follow-up time was 6.9
years for cases, 10.1 years for controls, 6.5 years for
historical cases, and 8.2 years for contemporaneous
cases. A total of 75 cases with HHT (11.1%) and
488 controls (7.3%) died. The overall crude
mortality rate in cases with HHT was 11.0 per
1,000 patient-years (95% confidence interval [CI]
8.8–13.9), and in their matched controls the
comparable figure was 6.1 per 1,000 patient-years
(CI 5.5–6.6). We found a worse survival in patients
with HHT compared with their age-, sex-, and
practice-matched controls with a hazard ratio (HR)
for death of 2.03 (CI 1.59–2.60, p , 0.0001)
(figure). The proportional hazards assumption did
not hold true for these data and thus the adjusted
HRs were split into 3 time periods of follow-up
demonstrating a higher mortality in the time period
closest to a recorded diagnosis of HHT: 0–3 years
(HR 4.57, CI 2.56–8.18, p , 0.001), 3–10 years
(HR 2.07, CI 1.42–2.99, p , 0.001), and 10 or
more years (HR 1.45, CI 0.95–2.21, p , 0.001).
Median age at death was 77 years for cases with
HHT (interquartile range 67–85 years) and 80
years for controls (interquartile range 74–87 years).
Survival in cases with HHT did not differ between
males and females (HR 1.06, CI 0.66–1.70, p 5
0.825) but was higher in those from the most
affluent socioeconomic group compared with the
least (HR 1.15, CI 1.04–1.27, p 5 0.007). After
stratification by age, mortality was increased for
both those aged 60 years and older on entry to the
study (HR 1.60, CI 1.17–2.21, p 5 0.004) and for
those younger than 60 years compared with matched
controls (HR 6.74, CI 4.2–10.8, p , 0.0001).
Sensitivity analysis. Three hundred seventy-three (55%)
cases of HHT had a contemporaneous diagnosis within
THIN, with the remaining 302 (45%) cases of
HHT coded as historical. ORs for complications in
Table 1 Characteristics of cases and controls
Cases (n 5 675) Controls (n 5 6,696) OR (95% CI)
Mean age, y 53.8 (SD 23.0) 53.9 (SD 22.8)
Age group, y
<15 29 (4.3) 269 (4.0) Matching variable
15–49 256 (38.0) 2,547 (38.0)
501 390 (58.0) 3,880 (58.0)
Sex
Male 249 (36.9) 2,469 (36.9) Matching variable
Female 426 (63.1) 4,227 (63.1)
Socioeconomic status
1 (least deprived) 182 (27.0) 1,899 (28.4) Reference
2 134 (19.9) 1,423 (21.3) 1.00 (0.79–1.28)
3 133 (19.7) 1,250 (18.7) 1.14 (0.89–1.46)
4 111 (16.4) 1,068 (16.0) 1.13 (0.86–1.48)
5 (most deprived) 67 (9.9) 671 (10.0) 1.10 (0.79–1.53)
Missing 48 (7.1) 385 (5.75) 1.62 (1.03–2.55)
Smoking status
Never smoker 260 (38.5) 2,841 (42.4) Reference
Ex-smoker 161 (23.9) 1,231 (18.4) 1.47 (1.19–1.83)
Current smoker 114 (16.9) 1,078 (16.1) 1.17 (0.92–1.48)
Unknown/missing 140 (20.7) 1,546 (23.1) 0.93 (0.72–1.19)
Diabetes
Never coded as diabetic 619 (91.7) 6,233 (93.1) Reference
Ever coded as diabetic 56 (8.3) 463 (6.9) 1.24 (0.92–1.67)
Hypertension
Never coded as hypertensive 531 (78.7) 5,258 (78.5) Reference
Ever coded as hypertensive 144 (21.3) 1,438 (21.5) 0.98 (0.78–1.23)
Abbreviations: CI 5 confidence interval; OR 5 odds ratio.
Data are n (%) unless otherwise indicated.
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HHT were similar between contemporaneously and
historically diagnosed patients (data not shown).
Survival in contemporaneous cases was worse than in
their matched controls (HR 1.61, CI 1.13–2.30, p 5
0.008) and the same pattern was evident when looking
at the survival of historical cases compared with controls
(HR 2.57, CI 1.81–3.66, p , 0.0001). Age-adjusted
survival in historically diagnosed HHT cases was worse
than that in those diagnosed contemporaneously (HR
2.93, CI 1.80–4.75, p , 0.0001).
DISCUSSION We have identified several neurologic
sequelae (migraine, cerebral abscess, and stroke) and
bleeding complications (anemia, epistaxis, and gastro-
intestinal bleeding) that are more common in patients
with HHT. We observed a 2-fold increase in mortality
in patients with HHT compared with controls.
The strengths of this study are the combination of
a relatively large number of participants (containing
data from almost 700 patients with HHT) and the
long period of follow-up—in excess of 20 years for
some—which would be more challenging to achieve
in a prospectively designed clinical study. Our
findings are population-based and hence provide rep-
resentative estimates for complications and survival
for the UK population, minimizing certain biases that
can arise as a consequence of case-series analysis from
specialist centers. The case-control design allows
comparative estimates of relative risk to be made
against a matched control group providing new data
in addition to those generated by previous studies that
mainly used descriptive analyses of complication fre-
quencies in HHT-only cohorts. Our survival analysis
compares mortality between cases with HHT and
matched controls from the general population rather
than relying on estimated life expectancies from life
tables14 and includes a population more than 10 times
larger than the previous largest case-control study esti-
mating survival.15
The potential limitations of this study require con-
sideration. We were only able to study individuals
clinically diagnosed with HHT. However, we expect
a diagnosis of HHT recorded in THIN to have a rel-
atively high specificity because in the UK National
Health Service we anticipate that most diagnoses will
be made in secondary care in conjunction with
Table 2 Crude and adjusted ORs of complications in cases with HHT vs controls
Complication
Cases (n 5 675),
n (%)
Controls (n 5 6,696),
n (%)
Crude OR
(95% CI) p Value
Adjusted ORa
(95% CI) p Value
Neurologic
Stroke 37 (5.5) 212 (3.2) 1.81 (1.25–2.66) 0.002 1.76 (1.20–2.58) 0.004
TIA 14 (2.1) 92 (1.4) 1.56 (0.87–2.82) 0.146 1.52 (0.84–2.76) 0.167
Intracerebral hemorrhage 4 (0.6) 20 (0.3) 2.00 (0.68–5.85) 0.21 1.99 (0.68–5.84) 0.21
Cerebral abscess 3 (0.4) 1 (0.01) 30.0 (3.12–288.4) 0.003 29.3 (3.03–282.8) 0.004
Migraine 71 (10.5) 448 (6.7) 1.68 (1.28–2.20) ,0.001 1.67 (1.29–2.20) ,0.001
Seizure 8 (1.2) 62 (0.9) 1.29 (0.61–2.71) 0.50 1.26 (0.60–2.66) 0.54
Hemorrhagic
Anemia 135 (20.0) 401 (6.0) 4.42 (3.51–5.55) ,0.001 4.41 (3.50–5.56) ,0.001
Epistaxis 177 (26.2) 230 (3.4) 11.6 (9.10–14.7) ,0.001 11.4 (8.99–14.5) ,0.001
Gastrointestinal hemorrhage 10 (1.5) 16 (0.2) 6.08 (2.75–13.4) ,0.001 6.13 (2.76–13.6) ,0.001
Hemoptysis 16 (2.4) 77 (1.2) 2.13 (1.23–3.70) 0.007 1.99 (1.14–3.46) 0.015
Cardiovascular comorbidities
Cardiac failure 30 (4.4) 141 (2.1) 2.39 (1.53–3.71) ,0.001 2.37 (1.53–3.70) ,0.001
Ischemic heart disease 53 (7.9) 429 (6.4) 1.25 (0.90–1.72) 0.184 1.19 (0.86–1.65) 0.289
Myocardial infarction 33 (4.9) 217 (3.2) 1.53 (1.03–2.27) 0.034 1.46 (0.98–2.17) 0.06
Venous thromboembolism 18 (2.7) 154 (2.3) 1.18 (0.71–1.94) 0.527 1.12 (0.68–1.86) 0.643
Malignancies
Lung cancer 5 (0.7) 37 (0.6) 1.36 (0.53–3.49) 0.524 1.20 (0.46–3.08) 0.712
Breast cancer 10 (1.5) 117 (1.8) 0.85 (0.44–1.63) 0.623 0.86 (0.45–1.65) 0.647
Prostate cancer 3 (0.4) 56 (0.8) 0.50 (0.15–1.63) 0.25 0.49 (0.15–1.60) 0.235
Colon cancer 6 (0.9) 22 (0.3) 2.76 (1.11–6.85) 0.029 2.76 (1.10–6.90) 0.03
Abbreviations: CI 5 confidence interval; HHT 5 hereditary hemorrhagic telangiectasia; OR 5 odds ratio.
a Adjusted for smoking status using conditional logistic regression.
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clinical genetics physicians, with details on diagnosis
and complications sent back to the primary care phy-
sician. Hence, we consider it unlikely that a primary
care physician would code a patient as having HHT
unless supported by evidence from a specialist center.
Nonetheless, we acknowledge that in the absence of
external validation of our cases of HHT, we cannot
exclude the possibility of a small degree of diagnostic
misclassification that if present may reduce the size of
associations observed. We are also unable to exclude
the possibility that patients with HHT may visit their
primary care physician more often, and may be more
likely to have some of the minor complications diag-
nosed at a lower threshold than the control popula-
tion. However, we believe this is unlikely for the
more severe events, such as cerebral abscess, stroke,
and death, which are usually events noted in a sec-
ondary care setting and subsequently recorded in pri-
mary care records. We did not detect an increased risk
of certain complications (such as intracerebral hemor-
rhage) that are well-documented possible sequelae of
HHT.3 This may reflect issues of ascertainment
inherent in primary care databases resulting from
the miscoding of complications (e.g., coding intrace-
rebral hemorrhage as stroke). Finally, although our
data show a higher mortality in patients with HHT
compared with controls, we are not able to comment
on whether this poorer survival is related directly to
complications of HHT because we could not access
patients’ clinical notes or death certification to con-
firm the cause of death. A previous study found that
slightly more than a third of deaths in patients with
HHT could be attributed directly to complications of
the disease.14 We used all available data, and as a
consequence there was no power calculation, and
the uncertainty of the estimates is indicated by the
95% CIs.
We found a higher risk of neurologic (cerebral
abscess, stroke, and migraine) and bleeding complica-
tions (anemia, epistaxis, hemoptysis, and gastrointes-
tinal hemorrhage) in individuals who had HHT
compared with controls. A recent epidemiologic
study using US health insurance data for surveillance
of HHT and its complications found the disease, and
hence its complications, to be underrecognized in this
database.24 This may be a consequence of the rela-
tively high costs of US health insurance, because in-
dividuals unable to afford health insurance are likely
to be underrepresented in the dataset. The UK
National Health Service has a much wider coverage,
with close to 98% of the population registered with a
general practitioner.25 Most published work looking
at complications in the disease are descriptive analyses
in cohorts often recruited from specialist HHT cen-
ters. On comparing the prevalences of clinical com-
plications, most of our estimates are lower than those
cited in the existing literature (table 3). We deliber-
ately included for comparison only studies in which
the prevalence of cerebral and pulmonary AVMs in
the HHT population was not stated because we did
not have this information available for our cohort.
The lower prevalence of identified complications in
our study may be a consequence of the ascertainment
of complications being lower in a primary care data-
base than in a clinical study with access to detailed
clinical data that are collected in secondary and ter-
tiary medical care centers. Alternatively, previous
studies may have overestimated the prevalences of
complications because of a referral and selection bias
if more complicated or severe cases are seen in the
specialist centers from which the cohort is derived. It
is widely acknowledged that many cases of HHT in
the general population remain undiagnosed. While
some symptomatic patients presenting to health care
services elude diagnosis because clinicians do not have
a sufficiently high index of suspicion for HHT, there
are likely to be other HHT gene carriers who remain
undiagnosed simply because they display a milder
phenotype of the disease.
We noted higher odds of colonic carcinoma in our
cases with HHT (in approximately 1%), which may
be a true association or alternatively be the conse-
quence of misclassification with juvenile polyposis
syndrome, a disease known to be associated with
the HHT phenotype via a shared mutation in the
SMAD4 gene.26,27 Juvenile polyposis syndrome is
associated with up to 40% increased risk of colon
Figure Kaplan–Meier plot of survival from index date among cases with HHT
compared with age-, sex-, and primary care-matched controls
Index date is the first recorded diagnosis of HHT appearing in health records (if a “contem-
poraneous” case). If a diagnosis of HHT was made before a patient’s practice joined the THIN
database (a “historical” case), the index date was the date the practice started contributing
longitudinal data to THIN. The index date for controls was defined as the index date of the
matched case. CI5 confidence interval; HHT5 hereditary hemorrhagic telangiectasia; HR5
hazard ratio; THIN 5 The Heath Improvement Network.
1890 Neurology 84 May 5, 2015
ª 2015 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
cancer,28 and this may explain the increase in bowel
cancer risk observed in our population.
Overall, our data from a population-based sample
of patients with HHT suggest that the risks of com-
plications of HHT may not be as high as previous
studies have suggested. Future work could help to fur-
ther validate our findings by accessing the primary
and secondary care records of the individuals in the
THIN database included in this study, although pre-
vious audit has shown a relatively high level of com-
pleteness of clinical diagnostic data.29
Our data demonstrate that patients with HHT
have a poorer survival compared with controls.
Median age at death was 77 years in cases with
HHT compared with 80 years in controls, a decrease
of 3 years. The published literature of survival in
HHT is relatively small, consisting of 3 articles13–15
and an abstract16 studying a total of 283 cases, com-
pared with our analysis of 675 individuals who had
the disease. These studies have either compared sur-
vival in HHT cases with that in matched controls14,15
or have examined the parents of HHT-affected
offspring and compared the age at death of parents
who had HHT with that of parents without the dis-
ease13,16 (studies summarized in table 4). In our data,
the HRs for death were highest in the 3 years after
initial diagnosis and decline latterly, which may
reflect the nature in which some patients with
HHT are diagnosed, for example, after a life-
limiting complication such as stroke. Our data per-
tain to the presence or absence of a recorded diagnosis
of HHT, and hence we were unable to explore the
impact of any differences in clinical management
strategies.
A substantial number of the patients with HHT
included in THIN had a historical rather than con-
temporaneous date of diagnosis. While both groups
had worse survival than their matched controls, the
HR for death was almost 3 times as high in the histor-
ically diagnosed group of HHT cases compared with
the contemporaneous cases. This may be explained by
more severe or symptomatic disease in the historical
cases as a consequence of presentation earlier in life
compared with those who were diagnosed as incident
Table 3 Comparison of our prevalence estimates for complications of hereditary hemorrhagic telangiectasia
with those made in other studies (excluding any that confirmed the presence of pulmonary
arteriovenous malformations)
Complication Donaldson (current study), % Range of estimates from other literature, % References
Stroke 5.5 7.2–9 6, 9, 32
TIA 2.1 4.1 9
Intracerebral bleed 0.6 2.1 3
Cerebral abscess 0.4 0.03–9.1 6, 7, 33–35
Migraine 10.5 33–40 10, 36
Anemia 20 29 37
Epistaxis 26.2 90–99 37–39
Gastrointestinal bleeding 1.5 13–30 38, 40
Table 4 Summary of studies of survival in HHT
Year
published Authors
Study size
(cases) Methodology Cases vs controls
Mean
Follow-up,
y
Mean difference in
age at death in
cases
vs controls
(reduction in years)
2014 Donaldson et al.
(current study)
675 Prospective epidemiologic study HHT cases vs age-, sex-, and primary
care-matched controls
11.7a 3.0b
2010 Edwards et al.16 113 Cross-sectional questionnaire
study of HHT offspring
HHT-affected parents vs unaffected
parents
NA 8.3
2006 Sabba et al.13 40 Retrospective clinical study HHT-affected parents vs unaffected
parents
NA 6.8b
2005 Kjeldsen et al.15 73 Prospective clinical/epidemiologic
study
HHT cases vs age-, sex-, and location-
matched controls
7.5 0
1999 Kjeldsen et al.14 57 Prospective clinical/epidemiologic
study
HHT cases vs “expected mortality”
calculated from life table analysis
21 NA
Abbreviation: HHT 5 hereditary hemorrhagic telangiectasia; NA 5 not available.
aMedian follow-up.
bMedian age at death.
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cases during the course of our period of data collec-
tion. This is consistent with our clinical experience
that developments such as the formulation of the
diagnostic Curaçao criteria,30 publication of interna-
tional guidelines for the diagnosis and management of
HHT,31 increasing use of genetic testing, and, per-
haps, an increased awareness of the disease, have con-
tributed to diagnosis of more patients before they are
severely symptomatic.
We present evidence from a large, representative
primary care database confirming that on average a
diagnosis of HHT is associated with a 3-year reduc-
tion in median age at death and providing quantita-
tive estimates of complication risks in HHT
compared with matched controls. While some pa-
tients undoubtedly experience significant morbidity
due to HHT, our study suggests that complication
rates among the diagnosed population may not be
as high as previously thought. This may change the
information provided in counseling newly diagnosed
patients when discussing the natural history of the
disease. Because many of these complications are
amenable to intervention, early diagnosis and treat-
ment should remain the priority for responsible
clinicians.
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